In Week of Mar 28, 2026, Sakar Healthcare Ltd (Hospitals) is outperforming Nifty 500 with +34.0% relative strength. Fundamentals: Average. On a 11-week streak.
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
Based on Q3 FY26 earnings • Updated Feb 22, 2026
What: BALA facility gaining global strategic relevance with 60% oncology growth target for FY27
“The EU GMP approved oncology facility at BALA has begun to gain significant strategic relevance globally with partners across Europe and emerging markets increasingly relying on SAR”
What: Targeting 30% margins in oncology segment vs current 26% overall EBITDA
“So when we had conceptualized oncology, we were expecting a margin somewhere around 30%. So that is the target we would be trying to achieve.”
What: Strengthened positioning in APAC, Latin America, Africa, CIS and parts of Europe
“enhanced profitability and strengthened SAP's position positioning in APAC Latin America Africa CIS and parts of Europe.”
Earnings deceleration risks from management commentary
Trigger: Below-target oncology segment growth
Management view: Management has set specific targets but not explicitly discussed risks
Monitor: Quarterly oncology segment growth vs 60% target
Trigger: Disruption in oncology segment
Management view: Not explicitly discussed as a risk
Monitor: Oncology segment revenue contribution percentage
Key quotes from recent conference calls
“The EU GMP approved oncology facility at BALA has begun to gain significant strategic relevance globally with partners across Europe and emerging markets increasingly relying on SAR — Management”
“So when we had conceptualized oncology, we were expecting a margin somewhere around 30%. So that is the target we would be trying to achieve. — Management”
“31 crores out of which 19 is export and 12 is domestic — Management”
“60% growth for the full year or for the next next next year I'm talking about... for FY27 60% growth — Management”
Forward-looking targets from management for FY27
Revenue Growth Target
60%
OPM Guidance
30%
Key Milestones
• 60% oncology segment growth in FY27
• 30% margins in oncology segment
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +63% | +12% | Accelerating |
| PAT (Net Profit) | +100% | +6% | Stable |
| OPM | 26.0% | -100 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Feb 22, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Sakar Healthcare Ltd's latest quarterly results (Dec 2025) show
Sakar Healthcare Ltd's profit is growing with an stable trend.
Sakar Healthcare Ltd's revenue growth trend is accelerating.
Sakar Healthcare Ltd's operating margin is volatile.
Sakar Healthcare Ltd's long-term compounding rates
Sakar Healthcare Ltd's earnings growth is stable with improving on a sequential basis.
Sakar Healthcare Ltd's trailing twelve month (TTM) performance
Sakar Healthcare Ltd appears significantly overvalued based on our fair value analysis.
Sakar Healthcare Ltd's current PE ratio is 45.7x.
Sakar Healthcare Ltd's current PE is 45.7x.
Sakar Healthcare Ltd's price-to-book ratio is 3.8x.
Sakar Healthcare Ltd is rated Average with a fundamental score of 53/100. This score is calculated from objective financial metrics
Sakar Healthcare Ltd has a debt-to-equity ratio of N/A.
Sakar Healthcare Ltd's return ratios over recent years
Sakar Healthcare Ltd's operating cash flow is positive (FY2025).
Sakar Healthcare Ltd currently does not pay a significant dividend (yield 0.00%).
Sakar Healthcare Ltd's shareholding pattern (Dec 2025)
Sakar Healthcare Ltd's promoter holding has remained stable recently.
Sakar Healthcare Ltd has been outperforming Nifty 500 for 11 consecutive weeks, indicating consistent outperformance.
Sakar Healthcare Ltd is an established outperformer with 11 weeks of consecutive Nifty 500 outperformance.
Sakar Healthcare Ltd has 3 key growth catalysts identified from recent earnings analysis
Sakar Healthcare Ltd has 2 key risks worth monitoring
In Q3 FY26, Sakar Healthcare Ltd's management highlighted
Sakar Healthcare Ltd's management has provided the following forward guidance for FY27
Based on quantitative research signals, here is why Sakar Healthcare Ltd may be worth studying
Sakar Healthcare Ltd investment thesis summary:
Sakar Healthcare Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.
